Home/ Stocks/ JBIO

Jade Biosciences, Inc. Common Stock

JBIO XNAS

$15.07 +1.26 (+8.94%) ▲ 15-min delayed

Open

$14.16

High

$15.11

Low

$13.65

Volume

596.5K

Market Cap

$958.41M

About Jade Biosciences, Inc. Common Stock

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 55 Website →

Related Market News

No specific coverage for JBIO yet. Check out our latest market news or earnings calendar.

Get JBIO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Jade Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.